-
Autolus Therapeutics NASDAQ:AUTL Autolus Therapeutics plcis a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.
Location: Scale Space Building, White City, London, W12 7RZ, United Kingdom | Website: www.autolus.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
641.8M
Cash
705.9M
Avg Qtr Burn
-39.15M
Short % of Float
8.15%
Insider Ownership
18.03%
Institutional Own.
75.92%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
obe-cel (AUTO1) (CD19) Details Acute lymphoblastic leukemia, Cancer, Blood cancer Big Mover™ Suspected Mover™ Susp. Mover™ | PDUFA Approval decision | |
AUTO4 Details Peripheral T cell cancer | Phase 1/2 Update | |
AUTO8 (BMCA & CD19) Details Multiple myeloma | Phase 1 Data readout | |
AUTO6NG Details Solid tumor/s, Neuroblastoma | Phase 1 Data readout | |
AUTO1/22 (CD19 & CD22) Details Acute lymphoblastic leukemia, Cancer, Leukemia | Phase 1 Data readout | |
obe-cel (AUTO1) (CD19) Details Systemic lupus erythematosus, Autoimmune disease | Phase 1 Data readout | |
obe-cel (AUTO1) (CD19) Details Lymphoma, Leukemia, Cancer, Central nervous system illness, primary central nervous system lymphomas | Phase 1 Update | |
obe-cel (AUTO1) (CD19) Details Lymphoma, Non-Hodgkin lymphoma, Chronic lymphocytic leukemia, Cancer, Leukemia | Phase 1 Update | |
AUTO5 Details T-cell lymphoma | Phase 1 Initiation | |
AUTO3 (CD19, CD22) Details Lymphoma, Diffuse large B cell lymphoma, Cancer | Failed Discontinued |